Safety of LED Red Light Nasal Devices
LED red light nasal devices appear to be safe and well-tolerated based on available evidence, with no serious adverse events reported in clinical studies, though long-term safety data remain limited.
Safety Profile
The safety evidence for intranasal red light therapy devices is reassuring across multiple clinical contexts:
No serious adverse events have been documented in controlled trials using intranasal phototherapy devices. A 2011 systematic review examining three different intranasal phototherapy devices (including red light wavelengths) found that clinical use was safe and well-tolerated 1.
In a randomized controlled trial of 199 COVID-19 patients using a device with 635 nm intranasal red LED, there were zero deaths and zero severe adverse events in the treatment group, compared to 1 death and 3 hospitalizations in the control group receiving standard care only 2.
A 2023 study using combined visible (660 nm) and infrared (940 nm) light for allergic rhinitis demonstrated clinical improvement without reported adverse effects over a 4-week treatment course 3.
Important Caveats and Distinctions
Device Type Matters
Not all red light devices are equivalent in safety profile:
Nasal LED devices (like those studied for allergic rhinitis and COVID-19) use diffuse light-emitting diodes and have demonstrated excellent safety profiles 1, 2, 3.
Laser-based devices designed for other applications (such as myopia treatment) can reach safety limits rapidly. A 2026 evaluation found some laser devices reached ANSI group 1 safety limits within 1.4-2.8 seconds of exposure, raising significant safety concerns 4.
Long-Term Safety Uncertainty
The primary limitation in the evidence base is the lack of long-term prospective studies:
While phototherapy causes DNA damage in treated tissues, current evidence does not demonstrate predisposition to carcinogenesis 1.
However, the 2011 review explicitly states that long-term prospective studies are required to verify this finding 1.
Most clinical trials have follow-up periods of only weeks to months, with one study reporting 12-month follow-up showing no concerning late effects 5.
Clinical Context
For allergic rhinitis treatment, intranasal phototherapy with red light (660 nm) has shown:
- Significant improvement in clinical symptoms including nasal itching, discharge, obstruction, and sneezing 3.
- 70% improvement in allergic rhinitis symptoms after 14 days of treatment in pediatric and adult populations 6.
- Good tolerability with devices designed for self-administration at home 6.
Bottom Line for Clinical Practice
LED-based intranasal red light devices can be considered safe for short to medium-term use based on current evidence, with the following considerations:
- Ensure the device uses LED technology rather than laser-based systems 4.
- Devices emitting wavelengths around 660 nm appear most studied for nasal applications 6, 3.
- Patients should be counseled that long-term safety data beyond one year are limited 1.
- Supervision by a qualified clinician is advisable, particularly for initial treatments 7.